Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal control of liver-only colorectal cancer metastases with cetuximab and hepatic artery infusion chemotherapy
2007-004632-24Phase 2Active
- Sponsor
- ARTBIO
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by ARTBIO. Primary endpoint: Complete macroscopic resection rate of liver metastases (R0+R1). Started Nov 2007; status: active.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-004632-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004632-24.